secwatch.observer — SEC 8-K summary
======================================

Issuer:     Gain Therapeutics, Inc. (GANX)
CIK:        0001819411
Form:       8-K
Filed at:   2025-10-14T23:59:59+00:00
Accession:  0001104659-25-099343
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gain Therapeutics hosts KOL event highlighting emerging GT-02287 Parkinson's data
--------------------------------------------------------------------------------

- Virtual KOL event on Oct 14, 2025 featured Dr. Karl Kieburtz (Univ. of Rochester) and Dr. Kenneth Marek (Institute for Neurodegenerative Disorders).
- Presentation focused on biomarkers, clinical endpoints, and path to disease modification for GT-02287.
- GT-02287 is a GCase-targeting small molecule for Parkinson's disease; emerging data was contextualized.
- Slides from the event were furnished as an exhibit; no new quantitative data or financial guidance provided.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819411/000110465925099343/0001104659-25-099343-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819411/000110465925099343/tm2528732d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-099343

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer